Mikroscan Expands Offering with Leading Image Analysis Platforms
Some interesting news from Mikroscan last week getting in to the image analysis segment with partnerships with companies such as Indica Labs and Visiopharm for collaborative platforms with Mikroscan’s Qumulus platform. Mikroscan has historically provided a lower-volume, lower-cost desktop scanning solution ideal for real-time collaborations for peer reviews, frozen sections, quality assurance and rapid on-site evaluations (ROSE) for cytopathology, recognizing the telepathology segement in the digital pathology market. Now they add image analysis, the second main value driver for digital pathology after “slide somewhere else” value driver for remote viewing/telepathology applications. Lastly, I agree with the company’s statements about the need for both remote viewing applications as well as image analysis applications that will be an essential component to national programs such as the cancer moonshot initiative to facilitate data transfer, data mining and data analytics.
Company provides enhanced tools for life science researchers to make discoveries more quickly and accurately
Mikroscan Technologies, maker of affordable desktop real-time telepathology and whole-slide imaging solutions, recently announced expanded image analysis tools for digital pathology through key partnerships with leading providers of quantitative tissue pathology software.
These collaborations enable Mikroscan to offer additional image analysis tools for biomarker evaluation and quantification, as well as for disease-specific and stereology applications. These capabilities, along with Mikroscan’s Qumulus™ image management system, better support pathologists in biopharmaceutical companies, contract research organizations, research institutes, academic medical centers, and hospitals.
“We are pleased to provide a more comprehensive solution by connecting users with the ability to quantitatively evaluate digital pathology images, resulting in quicker, repeatable, and more precise results than manual assessment,” said Mikroscan’s president Martin Stuart, PhD.
In a recent study published in Modern Pathology, digital image analysis was shown to outperform manual biomarker assessment in breast cancer. “These data show that image analysis can be integral in developing patient-specific cancer immunotherapy, a treatment technique now rigorously supported by the National Cancer Moonshot and one we are proud to facilitate,” Stuart said. “Our role in driving the ever-increasing adoption of telepathology and whole-slide imaging, through affordable, portable solutions, is one we take very seriously.”
With an open application programming interface, the Qumulus system can integrate with any leading image analysis provider. Recent additions to Mikroscan’s image analysis partners include the HALO® platform from Indica Labs and the ONCOTOPIX™ for image analysis in cancer as well as the BIOTOPIX™ platform for non-cancer tissue research and STEREOTOPIX™ for all stereology solutions developed by Danish based Visiopharm. Both companies have successfully deployed their tools in research, clinical, and educational organizations around the world.
Gary Pace, Mikroscan’s chairman of the board, said “Collaboration with image analysis providers is just one component of a strong, focused partner program that we will continue to expand in order to better serve pathologists.”
About Mikroscan Technologies, Inc.
Mikroscan provides affordable desktop telepathology and whole-slide imaging solutions designed to promote the practice of pathology from a distance. Our mission is to distribute pathology expertise on demand, regardless of location, and in the process reduce healthcare costs and improve patient care. For more information about Mikroscan, please visit www.mikroscan.com.
